Lincoln Pharmaceuticals Ltd consolidated Q4FY21 net profit at Rs. 12.57 crore

LINCOLN PHARMACEUTICALS LTD. has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.82.11 crores during the period ended March 31, 2021 as compared to Rs.115.47 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.12.57 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.13.48 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.6.29 for the period ended March 31, 2021 as compared to Rs.6.74 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 82.11 crs	₹ 115.47 crs	-28.89%
Net Profit	₹ 12.57 crs	₹ 13.48 crs	-6.75%
EPS	₹ 6.29	₹ 6.74	-6.68%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.82.11 crores during the period ended March 31, 2021 as compared to Rs.82.65 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.12.57 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.8.94 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.6.29 for the period ended March 31, 2021 as compared to Rs.4.47 for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 82.11 crs	₹ 82.65 crs	-0.65%
Net Profit	₹ 12.57 crs	₹ 8.94 crs	40.6%
EPS	₹ 6.29	₹ 4.47	40.72%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.429.84 crores during the 12 months period ended March 31, 2021 as compared to Rs.397.53 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.62.22 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.51.43 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.31.11 for the 12 months period ended March 31, 2021 as compared to Rs.25.72 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 429.84 crs	₹ 397.53 crs	8.13%
Net Profit	₹ 62.22 crs	₹ 51.43 crs	20.98%
EPS	₹ 31.11	₹25.72	20.96%

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Company's performance during the quarter and full year has been quite robust and considering that have recommended dividend of Rs. 1.50 per share. Company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in coming years. Our strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term."

Company is witnessing good traction in the export business, which is expected to get further boost once EU operations begins. Company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries. For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially. dermatology, gastro and pain management to complement its strong presence in acute segment.

Shares of LINCOLN PHARMACEUTICALS LTD. was last trading in BSE at Rs.320.8 as compared to the previous close of Rs. 327.25. The total number of shares traded during the day was 23080 in over 883 trades.

The stock hit an intraday high of Rs. 335.95 and intraday low of 319. The net turnover during the day was Rs. 7488362.

Source : Equity Bulls

Keywords